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Abstract
The protein deleted in malignant brain tumors (DMBT1) and the trefoil factor (TFF) proteins have all been proposed to have
roles in epithelial cell growth and cell differentiation and shown to be up regulated in inflammatory bowel diseases. A panel
of monoclonal antibodies was raised against human DMBT1gp340. Analysis of lung washings and colon tissue extracts by
Western blotting in the unreduced state, two antibodies (Hyb213-1 and Hyb213-6) reacted with a double band of 290 kDa
in lung lavage. Hyb213-6, in addition, reacted against a double band of 270 kDa in colon extract while Hyb213-1 showed no
reaction. Hyb213-6 showed strong cytoplasmic staining in epithelial cells of both the small and large intestine whereas no
staining was seen with Hyb213-1. The number of DMBT1gp340 positive epithelial cells, stained with Hyb213-6, was
significantly up regulated in inflammatory colon tissue sections from patients with ulcerative colitis (p,0.0001) and Crohn’s
disease (p = 0.006) compared to normal colon tissue. Immunohistochemical analysis of trefoil factor TFF1, 2 and 3 showed
that TFF1 and 3 localized to goblet cells in both normal colon tissue and in tissue from patients with ulcerative colitis or
Crohn’s disease. No staining for TFF2 was seen in goblet cells in normal colon tissue whereas the majority of tissue sections
in ulcerative colitis and Crohn’s disease showed sparse and scattered TFF2 positive goblet cells. DMBT1 and TFF proteins did
therefore not co-localize in the same cells but localized in adjacent cells in the colon. The interaction between DMBT1gp340
and trefoil TFFs proteins was investigated using an ELISA assay. DMBT1gp340 bound to solid-phase bound recombinant
dimeric TFF3 in a calcium dependent manner (p,0.0001) but did not bind to recombinant forms of monomeric TFF3, TFF2
or glycosylated TFF2. This implies a role for DMBT1 and TFF3 together in inflammatory bowel disease.
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Introduction
The gene Deleted in Malignant Brain Tumors 1 (DMBT1) was
identified more than a decade ago as a region of chromosome
10q25.3-q26.1 based on homologous deletions and lack of
expression in medulloblastoma, glioblastoma multiforme, lung
and gastrointestinal cancers and has been suggested as a potential
tumor-suppressor gene [1–5]. The DMBT1 gene encodes extra-
cellular secreted molecules with the longest variant featuring 13
scavenger receptor cysteine-rich (SRCR) domains separated by
SRCR interspersed domains (SIDs) [6].
The domain organization of DMBT1 indicates that CRP-ductin
[7], ebnerin [8] and hensin [9] are ortholog proteins in mouse, rat
and rabbit, respectively and the genomic structure and organiza-
tion further supported this view [10,11].
DMBT1 and CRP ductin are localized in epithelial cells on
mucosal surfaces and in skin that suggests a role for DMBT1 in
epithelial development [6,7,12,13]. This was supported by other
studies showing that hensin and ebnerin have a possible role in the
activation and differentiation of epithelial cells [14,15].
Besides the roles involved in cell differentiation and growth, a
role for DMBT1 in innate immunity has also been suggested. The
glycoprotein 340, gp-340, was purified from human bronchoalve-
olar lavage with a molecular weight of 340 kDa under reducing
SDS-PAGE conditions, where it was observed as a double band
(named as band A and B) [16]. Gp-340 was shown to interact
specifically with the collectin proteins surfactant protein A and D
(SP-A and -D), both are molecules involved in the mucosal
immune defense system [16,17]. Sequence data showed that gp-
340 is encoded by the DMBT1 gene, corresponding to the longest
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variant and hence the protein was named DMBTgp340 [6].
DMBT1gp340 was shown to be identical to salivary agglutinin [18],
a glycoprotein isolated from parotic saliva implicated in the
protection against dental caries through its binding and aggluti-
nation of Streptococcus mutans [19] and hence named DMBT1SAG.
DMBT1 proteins bind to other microorganisms like Helicobacter
pylori, several strains of streptococcus and viruses including Human
Immunodeficiency Virus Type 1 and influenza A virus [18,20,21].
The bacterial binding site has been confined to the SRCR domain
[22,23] The broad pathogen-specificity of DMBT1 is, at least in
part, based on it acting as pattern recognition receptor for
repeated phosphate and sulfate groups [24]. It seems therefore
likely that DMBT1 proteins also contribute to innate defense
against bacteria and viruses in the gastrointestinal and respiratory
tracts through direct interactions with microorganisms and/or
through interactions with SP-A or SP-D.
The two most common inflammatory bowel diseases (IBD) are
ulcerative colitis (UC) and Crohn’s disease (CD). The etiology for
both diseases is unknown but is considered to be multifactorial;
both involving the environment, the commensal gut flora and the
genetic makeup of an individual (recently reviewed in [25]). The
small intestine is most commonly affected by CD but any part of
the gastrointestinal tract can be involved whereas only the colon
and rectum are normally affected by UC. DMBT1 has been found
to be up regulated in an ex-vivo model using primary intestinal
epithelial cells and proinflammatory stimuli such as tumor necrosis
factor alpha and LPS from Salmonella enterica [26]. DMBT1 is also
up regulated in vivo in the small intestine and colon, shown in
intestinal biopsy samples from patients diagnosed with inflamma-
tory bowel disease such as UC and CD [26,27]. This was
measured on the mRNA level by quantitative real-time PCR and
shown on the protein level as well as by immunohistochemistry
using a rabbit polyclonal antibody raised against full-length
recombinant DMBT1 [26,27]. That DMBT1 has a direct
involvement in inflammatory bowel diseases in vivo was shown in
a mouse model where mice made deficient for DMBT1 were
found to have an enhanced susceptibility to dextran sulfate sodium
(DSS) induced colitis [27].
Porcine DMBT1 isolated from the stomach has been identified
as a possible binding molecule for the trefoil factor 2 (TFF2) [28].
Trefoil factors are a family of three members (TFF1, 2 and 3).
They are small compact proteins with trefoil motifs and an ability
to cross-link mucous and glycoproteins [29]. Cloning of human
TFF2 showed that TFF2 contained two TFF motifs and
recombinant expression in a yeast system showed that TFF2 is
expressed in a dimeric state but with or without an asparagine N-
linked glycosylation [30,31]. Cloning of human TFF3 showed that
it contains one TFF motif but recombinant expression in a yeast
system showed that the protein is can be purified as either a
monomeric or dimeric molecule where the latter is composed of
two monomers linked with a disulphide bridge [32,33]. TFF3 is
expressed in mucus-secreting cells on mucosal surfaces throughout
the human body, e.g. goblet cells in the colon, with a tissue profile
similar to SP-D and DMBT1gp340, whereas TFF1 and TFF2 show
a more restricted tissue localization [34]. Mice deficient for each of
the TFFs, made by gene-targeting disruption, all showed a
phenotype of decreased ability to regenerate mucosal healing after
injury by numerous inflammatory agents [35–37]. This implied
that TFF proteins play a protective role, with a function in
regeneration of mucosal epithelia. This was supported by the
finding that with a transgenic mouse mode overexpressing TFF2,
the mice showed an increased resistance to intestinal damage [38].
All TFF proteins have been found to be up regulated, on the RNA
level, in inflammatory bowel diseases like CD or UC (reviewed in
[39]).
Here we present data showing that the number of DMBT1gp340
positive epithelial cells is up regulated in the inflammatory bowel
diseases CD and UC. Furthermore, we found that DMBT1gp340
binds specifically to recombinant human dimeric TFF3 but not to
recombinant proteins of human glycosylated or non-glycosylated
TFF2 or monomeric TFF3.
Materials and Methods
Ethics Statement
Human Tissue used for analysis by SDS-PAGE/Western
blotting and immunohistochemistry.
Human tissues samples were from the tissue bank at the
Department of Pathology, Odense University Hospital, Denmark.
The Regional Scientific Ethical Committee for Southern Denmark
approved the use of human tissue samples for research purposes
(VF20050070) and samples were obtained from patients with
written informed consent. Normal human colon tissue was
obtained from patients undergoing resection for carcinoma of
the colon and samples were taken from regions several centimeters
away from the tumor. Colon tissue from patients with inflamma-
tory bowel disease was obtained from patients undergoing
resection for diagnostic or therapeutic purposes. Bronchoalveolar
lavage (BAL) was obtained from patients with written informed
consent undergoing lung washings for therapeutic purposes
including pulmonary alveolar proteinosis. The procedure was
approved by the London National Health Service Research Ethics
Committee.
Buffers and Reagents
Alkaline phosphatase-conjugated goat anti-mouse IgG (whole
molecule) antibody (Sigma-Aldrich, St. Louis, MO, USA); coating
buffer: 60 mM Na2CO3, 35 mM NaHCO3, 0.02% (w/v) NaN3,
pH 9.6; diethanolamine buffer: 10% (v/v) diethanolamine,
0.5 mM MgCl2, 0.02% (w/v) NaN3, pH 8.9; p-nitrophenylpho-
sphate, disodium salt (PNPP) (Boehringer Mannheim, Mannheim,
Germany); phosphate buffered saline (PBS): 123 mM NaCl,
10 mM sodium phosphate, 3 mM potassium phosphate, 0.02%
(w/v) NaN3, pH 7.4; PBS/BSA: PBS containing 0.1% (w/v) BSA;
sample buffer: 1.5% (w/v) sodium dodecylsulfate (SDS), 5% (v/v)
glycerol, 0.2% (w/v) bromphenol blue, 0.1 M Tris, pH 8.0; SSC
(20x): 3 M NaCl, 3.65 M sodium citrate, pH 7.2; substrate buffer:
100 mM NaCl, 100 mM Tris, 5 mM MgCl2; pH 9.5. Tris-
buffered saline (TBS): 140 mM NaCl, 10 mM Tris-HCl, 0.02%
(w/v) NaN3, pH 7.4; TBS/Tw: TBS containing 0.05% (v/v)
Tween 20 (polyoxyethylene sorbitan monolaurate, Merck Euro-
lab, Darmstadt, Germany); WB buffer: TBS/Tw with a final conc
of 0.5 M NaCl. All procedures took place at room temperature
unless otherwise stated.
SDS-PAGE and Western Blotting of BAL and Colon
Homogenates
The PhastSystem (Amersham Pharmacia Biotech, Uppsala,
Sweden) was used for SDS-PAGE and Western blotting. Tissue
and cells were homogenized in TBS with 10 mM EDTA, 10 mM
Tris, 5 mM iodoacetamide, 5 mM trans-4-(aminomethyl) cyclo-
hexanecarboxylic acid (Sigma-Aldrich), 1 mg/mL Aprotinin
(Boehringer Mannheim) and 1% (v/v) Triton X-100. The
homogenates were centrifuged at 10,0006g for 30 min at 4uC.
The supernatants were separated on 4–15% (w/v) polyacrylamide
gradient gels with the discontinuous buffer system. Samples were
reduced by heating at 100uC for 3 min in 40 mM dithiothreitol,
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1.5% (w/v) SDS, 5% (v/v) glycerol, 0.1 M Tris, pH 8.0, and
carboxamidated by the addition of iodoacetamide to a concen-
tration of 90 mM. Unreduced samples were heated in sample
buffer with 90 mM iodoacetamide. After the electrophoresis
proteins were blotted onto polyvinylidene difluoride membranes
(Immobilon P, Millipore, Bedford, MA, USA). The membranes
were blocked for 30 min in 0.1% Tween 20 in H2O followed by
overnight incubation at 4uC with the primary antibody (Hyb213-1
or Hyb213-6) at a concentration of 50 ng/mL in WB buffer. The
membranes were washed three times in WB buffer and then
incubated with a secondary alkaline-phosphatase-coupled rabbit
anti-mouse IgG antibody (diluted1:1000, Dako) in WB buffer. The
membranes were washed three times in WB buffer, followed by
one time in TBS/Tw and developed in substrate buffer with nitro
blue tetrazolium and potassium 5 bromo-4-chloro-3-indolylpho-
sphate.
Immunohistochemistry
Four mm sections were cut from neutral-buffered formaldehyde-
fixed paraffin embedded tissue blocks. Sections were mounted on
ChemMate Capillary Gap Slides (Dako, Glostrup, Denmark),
dried at 60uC, deparaffinized and hydrated.
DMBT1gp340: Antigen retrieval was performed using micro-
wave heating in Target Retrieval Solution (Dako). Three Tissue-
Tek containers (Miles Inc., Elkhart, IN, USA), each with 24 slides
in 250 mL buffer, were placed on the edge of a turntable inside the
microwave oven. Slides were heated 11 min at full power (900W),
then for 15 min at 400W. After heating, slides remained in the
buffer for 15 min. Antigen retrieval was followed by blocking of
endogenous biotin, using Dako’s Biotin-Blocking System (Dako).
Incubation with Hyb213-6 (625 ng/mL) was done for 25 min.
TFF proteins: Tissue sections for TFF1, TFF2 and TFF3 were
stained according to procedures describes previously [34]. Shortly,
antigen retrieval was performed for TFF1 and TFF3 as described
for DMBT1gp340, whereas antigen retrieval for TFF2 was
performed using 0.05% protease type XIV (pronase E, cat.
#P5147; Sigma-Aldrich) in TBS, pH 7.0, for 15 min at 37oC.
Polyclonal rabbit antisera (stock conc 1 mg/mL) against TFF1
(2239A), TFF2 (2240A), and TFF3 (2241A) were used at dilutions
1:2000, 1:1000 and 1:10,000, respectively.
Immunostaining of all sections was automated using the
ChemMate horseradish peroxidase/3,39-diaminobenzidine tetra-
hydrochloride detection kit (HRP/DAB, K5001; Dako) on the
TechMate 1000 instrument (Dako). Immunostaining was followed
by brief nuclear counter staining in Mayer’s hematoxylin. Finally,
cover slips were mounted with AquaTex (Merck Eurolab).
Controls were performed by replacing the primary monoclonal
antibody with an irrelevant monoclonal antibody of the same
subclass as the DMBT1gp340 antibodies or no primary antibody for
the polyclonal TFF antibodies.
The DMBT1gp340 staining of normal healthy tissue and
inflammatory colon diseased tissue (CD and UC) were quantified
with a score of 1 for a staining pattern seen in normal healthy
tissue (,25% of the epithelial cells), 2 for staining of 50% of
epithelial cells and 3 for staining of 100% of epithelial cells.
Scoring was performed independently and in a blinded manner by
two researchers (JMa and ON) and one pathologist (CF). Means
and standard derivation (SD) was calculated for each group
(normal tissue, CD and UC).
Purified Native DMBT1gp340 and Recombinant TFF
Proteins
Native DMBT1gp340 was purified from bronchoalveolar lavages
from patients with pulmonary alveolar proteinosis as described
previously [16]. All TFF proteins used, glycosylated and non-
glycosylated hTTF2 and monomeric and dimeric hFFT3, were
recombinant proteins expressed in a yeast system and purified as
described previously [31,33]. Reduced samples were analyzed by
SDS-PAGE as described above, except samples were analyzed on
4–12% (w/v) Novex Tris-Glycine polyacrylamide gradient gels
with the discontinuous buffer system according to manufactures
instructions (Invitrogen). SDS-PAGE gels with reduced
DMBT1gp340 was silver stained as described before [40] and
reduced TFF proteins were stained using SimplyBlue SafeStain
according to manufactures instructions (Invitrogen).
Binding of Human Recombinant Trefoil Factors to gp-340
All trefoil peptides used, glycosylated and non-glycosylated
hTTF2 and monomeric and dimeric hFFT3, were recombinant
proteins expressed in a yeast system and purified as described
previously [31,33]. Microtiter plates (Maxisorp, Nunc, Kamstrup,
Denmark) were coated with serial two-fold dilutions from 2 mg/
mL of recombinant forms of TFFs in coating buffer (0.1 M sodium
carbonate, pH 9.6) overnight at 4oC in a humidified chamber.
This incubation and all the following steps were carried out in a
volume of 100 mL/well and at room temperature unless specified.
Washes and incubations were carried out four times with TBS
with 0.05% Tween20 and 5 mM CaCl2 (TBS/Tw). The plates
were washed with and blocked for non-specific binding in 200 mL
of TBS/Tw for 2 h. After washing, the plates were incubated with
two-fold serial dilutions starting from 600 ng/mL of DMBT1gp340
for 2 h. After washing, plates were incubated with a rabbit
polyclonal anti-DMBT1gp340 antibody (K421) 10 mg/mL in TBS/
Tw for 2 h. A negative control for the calcium dependent binding
was performed with DMBT1gp340 in TBS/Tw and 10 mM
EDTA. The plates were washed and incubated for 2 h with
alkaline phosphatase-coupled goat anti-rabbit IgG (Sigma-Aldrich,
cat no A8025) diluted 1:2000 for one hour. After a final wash, the
bound enzyme was estimated by adding 1 mg/mL of 4-
Nitrophenyl phosphate (PNPP) in substrate buffer (10% (v/v)
diethanolamine, 0.5 mM MgCl2, pH 9.8) in the dark until
sufficient color development had occurred. The absorbance of
the 96 wells was read at 405 nm by means of a multichannel
spectrophotometer. Each sample was done in duplicate and
performed independently three times. Means and standard
derivation (SD) was calculated for each sample.
Statistics
The nonparametric statistical Kruskal-Wallis test was used to
compare means between groups. This was analyzed using the
software GraphPad Prism version 6. A p value less than 0.05 was
considered statistically significant.
Results
We have previously shown by RT-PCR that the main sites of
synthesis of DMBT1gp340 are the trachea, salivary gland, small
intestine, lung and stomach [6]. Immunohistochemical analysis
using Hyb213-1 as primary antibody revealed staining of
alveolar macrophages in the lung but no staining in the small
intestine that could justify the strong signal seen by RT-PCR
analysis. In contrast, a rabbit polyclonal antibody raised against
DMBT1gp340 (K421) reacted strongly with epithelial cells of the
small intestine and with alveolar macrophages in the lung and
weakly with alveolar type II cells [6].These results prompted us
to make a new round of monoclonal antibodies directed against
DMBT1gp340.
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Specificity of the Monoclonal Antibodies Hyb213-1 and
Hyb213-6 in Western Blotting of Lung Washings and
Colon Tissue Extracts
The specificity of the monoclonal antibodies against
DMBT1gp340 was analyzed by Western blots of crude lung lavage
and colon tissue extract separated on SDS-PAGE in the
unreduced state. Hyb213-1 reacted with both bands of 340 kDa
equally well in the reduced state (not shown) and with the double
band of 290 kDa seen in the unreduced state in lung washings
(Fig. 1). No reaction was seen when analyzing colon extract
(Fig. 1). Hyb213-6 directed against DMBT1gp340 reacted with the
same double band of 290 kDa in the unreduced state in lung
washings and in the colon extract. Hyb213-6 reacted with a
double band of approximately 270 kDa in the non-reduced state
(Fig. 1). Hyb213-6 does not react with DMBT1gp340 in the
reduced state in any tissue extracts analyzed (not shown). When
analyzing detergent solubilized alveolar macrophages from BAL
and BAL in parallel from the same person in the unreduced state,
a double band of approximately 290 kDa was observed with both
monoclonal antibodies (not shown). In saliva, both antibodies
recognized the same double band in the unreduced state as seen in
the lung (not shown).
Tissue Localization of gp-340 Using Hyb213-1 and 213-6
for Immunohistochemistry
Antigen retrieval was performed on normal human tissues using
microwave heating in Target Retrieval Solution. This technique
was more sensitive compared to the previous methodology where
citrate buffer was used as the antigen retrieval buffer [6]. Strong
immunostaining was seen in the serous acini and demilune cells of
the submandibular gland when both monoclonal antibodies
Hyb213-1 and Hyb213-6 were used for immunohistochemical
analysis (Fig. 2). Strong staining was also observed with Hyb213-6
in the tall columnar epithelial cells covering the villi and increasing
in intensity towards the bottom of crypts, including the crypts of
Lieberku¨hn in the small intestine, while no staining of epithelial
cells was observed when using Hyb213-1 (Fig. 2). Macrophages
in lamina propia of the intestine were clearly stained by Hyb213-1
while Hyb213-6 showed less intense staining. Both antibodies also
stained endothelia cells in all tissue sections analyzed. Hyb213-6
reacted equally well with the adsorptive crypt and luminal
epithelial cells in the colon and rectum while Hyb213-1 did not
recognize these epithelial cells (Fig. 2).
DMBT1gp340 is Up Regulated in Colon Epithelial Cells
from Patients with Inflammatory Bowel Disease
Immunohistochemical analysis was performed on normal colon
tissue (n = 13) and inflamed colon tissue from 18 patients
diagnosed with UC and 10 patients diagnosed with CD using
Hyb213-6. The number of DMBT1gp340 positive epithelial cells
was evaluated in segments of inflamed tissue in all patients and
compared with normal colon tissue. Normal colon tissue (n = 13)
showed clear but scattered staining of the absorptive epithelial cells
along the length of crypts in the colon in ten out of 13 samples
(Fig. 3). All patients diagnosed with UC (n= 18) or CD (n= 10),
except two patients in the UC group and one patient in the CD
group, showed uniformly strong cytoplasmic staining of epithelial
cells along the entire length of crypts in the colon (Fig. 3B). The
three patients that did not show strong cytoplasmic staining
showed moderately increased staining along the length of crypts in
the colon (data not shown).
The number of DMBT1gp340 positive epithelial cells was
quantified using a simple scoring matrix: A staining pattern seen
in normal healthy colon tissue (,25% of the epithelial cells) gave a
score of 1 whereas staining of approximately 50% of the cells gave
a score of 2 and staining of 100% of the epithelial cells gave as
score of 3. Using this scoring matrix, normal healthy colon tissue
had a mean (6standard derivation) of 1.462 (60.877) whereas CD
and UC had means of 2.900 (60.316) and 2.889 (60.323),
respectively (Table 1). Statistical analysis showed that the number
of DMBT1gp340 positive cells seen in CD and UC tissue sections
were statistically significantly increased when compared to normal
healthy tissue (normal vs CD: p= 0.0006; normal vs UC:
p,0.0001, Table 1). No statistically significant difference was
found between the number of DMBT1gp340 positive cells in CD
and UC (p.0.9999, Table 1).
TFF Staining in Colon Epithelial Cells from Patients with
Inflammatory Bowel Disease
As TFF proteins have been suggested as a putative receptor for
porcine stomach DMBT1, we performed immunohistochemical
analysis of the same tissue sections as for DMBT1gp340 with the
following groups: Normal (n = 13), CD (n= 10) and UC (n= 18).
These were stained using polyclonal antibodies against TFF1,
TFF2 and TFF3 as described previously [34]. TFF1-positive
goblet cells were found in 13 out of 13 normal tissue sections and
for all UC sections (n = 18) and DC sections (n = 10). The TFF1
staining was seen as a gradient of staining intensity with no
staining at the bottom of the crypts, increasing towards the lumen
for all normal tissue sections and for all sections in both the CD
and UC groups (Fig. 4). No TFF2 positive goblet cells were seen
in any normal colon tissue (n = 13) whereas most of the IBD tissue
sections contained scattered individual TFF2 positive goblet cells
(UC 12 out of 18; CD 8 out of 10) (Fig. 4). All goblet cells from the
base of the crypts to the epithelial surface at the top and onto the
luminal surface were stained positive for TFF3 in normal human
colon tissue (n = 13), as well as in both groups for CD (n= 10) and
UC (n= 18) (Fig. 4).
Figure 1. SDS-PAGE and Western blot of lung washing (L) and
colon tissue (C) in the non-reduced state. The blots were
incubated with the two monoclonal antibodies Hyb213-1, Hyb213-6
or stained for total protein content as described in the Materials and
Methods section. Black arrows: Double band (band A and B) of
DMBT1gp340 from bronchoalveolar lavage. Grey arrows: Double band of
DMBT1 from colon tissue.
doi:10.1371/journal.pone.0064441.g001
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As trefoil proteins have been reported to be up regulated in
inflammatory bowel diseases on the mRNA level compared to
normal tissue we wanted to see if this could be seen at the protein
level using the immunohistochemical staining methodology. A
dilution series of the TFF3 antibody was performed to find a
dilution with a weak, but discrete, staining in normal tissue that
would allow an easy visualization of up regulated TFF3 staining in
inflamed CD and UC colon tissues. The TFF3 antibody was
diluted from 1:10,000 to 1:3,200,000 times (Supplementary fig.
S1). Two dilutions of 1:400,000 and 1:600,000 were chosen and
these were applied to all normal colon tissue sections (n = 13) and
the two groups of CD (n= 10) and UC (n= 18) inflamed colon
tissue sections. However, when using this methodology it was not
possible to see any difference in the staining intensity between
normal tissue sections and inflamed CD or UC tissue sections as
the staining intensity varied within single tissue sections (Supple-
mentary fig. S1).
SDS-PAGE of Purified Native DMBT1gp340 and
Recombinant TFF Proteins
Reduced SDS-PAGE of native DMBT1gp340 purified from BAL
from patients with pulmonary alveolar proteinosis visualized by
silver staining showed a double band (band A and B) migrating
with a molecular weight around 300–350 kDa (Fig. 5A). Non
reduced and reduced SDS-PAGE of purified recombinant TFF
proteins and visualized by a coomassie-based staining showed a
single distinctive band for all TFF proteins (Fig. 5B). Non-
glycosylated TFF2 migrated with a molecular weight of approx-
imately 10 kDa and glycosylated TFF2 with a weight of 15 kDa.
Dimeric TFF3 migrated with a higher molecular weight than
monomeric TFF3 in the non-reduced state but both monomeric
and dimeric TFF3 migrated with a molecular weight of
approximately 6–7 kDa in the reduced state (Fig. 5B).
Binding of DMBT1gp340 to Solid-phase Human Trefoil
Factors
Binding of trefoil factors to DMBT1gp340 was analyzed using a
solid-phase assay where plates were coated with recombinant
forms of trefoil peptides: Glycosylated or non-glycosylated TFF2,
monomeric TFF3 or dimeric TFF3. Binding of DMBT1gp340 to
these peptides was detected using the polyclonal antibody K421
raised against DMBT1gp340 as detector and a secondary antibody
conjugated with alkaline phosphatase and substrate for color
indication. DMBT1gp340 did not bind either form of TFF2
proteins or monomeric TFF3 (Fig. 6A–C). However,
DMBT1gp340 interacted with dimeric TFF3 in a concentration
dependent manner and the binding was reaching near saturation
when using 600 ng/mL DMBT1gp340, which was the highest
concentration of DMBT1gp340 tested (Fig. 6D). No binding was
seen in the presence of EDTA (Fig. 6D).
Statistical analysis showed that interaction between
DMBT1gp340 and the dimeric TFF3 protein reached statistical
significance in all TFF3 concentrations tested when compared to
the control group with no dimeric TFF3 protein present (Fig. 6D).
When testing the highest concentration of dimeric TFF3 protein in
the presence of EDTA low binding values close to the binding
values with no TFF3 protein present were seen (Fig. 6D). This
was also reflected in the statistical analysis where no statistical
significance was found between the two groups (p = 0.1135,
Fig. 6D).
Figure 2. Immunohistochemical localization of DMBT1gp340 in human submandibular glands, small intestine and rectum. The tissues
were stained using monoclonal antibodies Hyb213-1 or Hyb213-6 directed against DMBT1gp340 and an indirect immunperoxidase technique and
counterstained with Mayer’s hematoxylin as described in the Materials and Methods section. A positive signal is shown by brown color. Asterisks
show striated ducts. Thin black arrow shows stained endothelial cells. Thick black arrow shows a stained macrophage in the lamina propia Original
magnification: 1006.
doi:10.1371/journal.pone.0064441.g002
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Discussion
We have previously used Hyb213-1 for immunohistochemical
localization of DMBT1gp340 and shown that it reacts with alveolar
macrophages, other tissue macrophages, and with ducts of parotid
glands but no reaction was seen in the small intestine [6]. This was
in strong contrast to the finding of a very strong signal for
DMBT1gp340 when analyzing for expression using RT-PCR [6].
Furthermore, a polyclonal anti-gp-340 antibody (K421) reacted
strongly with epithelial cells in the small intestine [6]. These results
prompted us to make new monoclonal antibodies directed against
DMBT1gp340 and one of the resulting antibodies was Hyb213-6.
When evaluating the two monoclonal antibodies in Western
blot analysis of crude lung washing showed that in a non-reduced
state both Hyb213-6 and Hyb213-1 reacted with a double band of
290 kDa and when detergent solubilized alveolar macrophages
from the same person were analyzed in parallel, a similar pattern
was observed. Amino acid sequence of peptides derived from these
bands has shown that they both were encoded by the DMBT1
gene [16]. When analyzing saliva by Western blot analysis in the
non-reduced state both antibodies reacted against the same bands
as found for lung lavage. This finding was supported by
immunohistochemical analysis of human submandibular glands
where both antibodies showed staining of the serous acini and
Figure 3. Immunohistochemical localization of DMBT1gp340 in normal human colon and inflammatory bowel diseases ulcerative
colitis and Crohn’s disease. The tissue sections were stained using the monoclonal antibody Hyb213-6 directed against DMBT1gp340 and an
indirect immunperoxidase technique and counterstained with Mayer’s hematoxylin as described in the Materials and Methods section. A positive
signal is shown by brown color. Original magnification: 1–3:50x; 4–6:200x.
doi:10.1371/journal.pone.0064441.g003
Table 1. Quantification of the number of DMBT1gp340
positively stained epithelial cells in normal human colon




samples Scoring Matrix Mean SD Statistics
1 2 3
Normal 13 10 0 3 1.462 0.877 Normal vs CD:
p = 0.0006*
CD 10 0 1 9 2.900 0.316 Normal vs UC: p,0.0001*
UC 18 0 2 16 2.889 0.323 CD vs UC: p.0.9999
Normal colon tissue and inflamed ulcerative colitis (UC) or Crohn’s disease (CD)
colon tissue was stained for DMBT1gp340 using the monoclonal antibody
Hyb213-6. The number of DMBT1gp340 positive epithelial cells was quantified
using a score of 1 for a staining pattern seen in normal healthy tissue (,25% of
the epithelial cells), 2 for staining of 50% of epithelial cells and 3 for staining of
100% of epithelial cells. Mean and standard derivation (SD) was calculated for
each group: Normal, Crohn’s disease (CD) and ulcerative colitis (UC). Statistical
analysis was performed using the nonparametric statistical Kruskal-Wallis test. A
p value less than 0.05 was considered statistical significant and marked with an
asterisk.
doi:10.1371/journal.pone.0064441.t001
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demilune cells. This is in accordance with previous results [41].
When analyzing colon extract in a non-reduced states Hyb213-6
reacted with a double band of approximately 270 kDa, whereas
these bands were not recognized by Hyb213-1. Hyb213-1 has
been shown to react with an O-linked sialidase-sensitive carbohy-
drate structure on DMBT1gp340 and cross-reacting with MUC7
[41]. Expression of MUC7 is restricted to the oral cavity and the
respiratory tract [42,43]. This implies that DMBT1gp340 expressed
in these tissues could have a tissue specific glycosylation explaining
why Hyb213-1 only reacts with DMBT1gp340 from these tissues
and not with DMBT1gp340 from the small or large intestines
(Fig. 3 and 4). Hyb213-6 has been shown to react with an epitope
on DMBT1gp340 that is lost during reduction of the disulphide
bridges in the molecule [41]. We find the same result for Hyb213-
6 in this paper (and unpublished results) and this indicates that the
epitope for Hyb213-6 is a structural dependent protein epitope
that is lost during the unfolding of the protein under reducing
conditions but present in all DMBT1 proteins investigated from
the gastrointestinal and respiratory tract (Fig. 1–3).
The two forms of DMBT1gp340 found in lung washings clearly
differ from the two forms found in the colon extract by molecular
mass. They likely differ in their glycosylation pattern as studies,
using mass spectrometry, of purified DMBT1gp340 from lung,
saliva or the proximal or distal colon, respectively, have shown
differential tissue specific glycosylation [44,45]. However, the
difference in molecular mass seen here between lung lavage and
colon extract DMBT1gp340 (Fig. 1) and previous studies could
simply be due to an inter-individual difference, as purified
DMBT1gp340 isolated from saliva from three different individuals
showed variance in size and glycosylation pattern [45]. At present
it is not known if this difference in size is due to tissue specific
glycosylation or inter-individual glycosylations as no study has
looked at DMBT1 proteins from different tissue or body fluids
from the same person.
Native DMBT1gp340 purified from BAL migrated under
reducing SDS-PAGE conditions as two bands (band A and B,
fig. 5A). This is in agreement with what we have previously found
[16]. Purified recombinant TFF proteins migrated under reducing
conditions with molecular weights of approximately 12 kDa (non-
glycosylated TFF2), 15 kDa (glycosylated TFF2) and 7 kDa
(monomeric and dimeric TFF3). This is also in agreement with
previous findings where the mass of the proteins were identified by
mass spectrometry [31]. The dimeric form of TFF3 has found to
be held together by a disulphide bridge between two monomeric
TFF3 molecules [33]. The disulphide binding will be reduced
under reducing conditions and result in two monomeric forms of
TFF3.This complies with what we observe here, where a shift in
the molecular weight of dimeric TFF3 from non-reduced SDS-
PAGE to reduced SDS-PAGE was observed and both monomeric
and dimeric TFF3 show the same molecular weight under
reducing conditions (Fig. 5).
We find here that the DMBT1 interaction with dimeric TFF3 is
calcium-dependent. This calcium dependency has also been
reported for the DMBT1 interaction with other secreted proteins
such as SP-A, SP-D, MBL and secretory IgA [16,17,46,47]. It is
somewhat surprising that the two porcine and human DMBT1
protein homologues display a different binding specificity with
regards to TFF proteins. The porcine DMBT1 was isolated from
stomach scrapings. We have previously shown that the stomach is
the primary organ for the expression of human TFF2, where the
Figure 4. Immunohistochemical localization of TFF1, 2 and 3 proteins in normal human colon and the inflammatory bowel diseases
ulcerative colitis and Crohn’s disease. Tissue sections were stained using polyclonal antibodies raised against TFF1, TFF2 and TFF3 and an
indirect immunperoxidase technique and counterstained with Mayer’s hematoxylin as described in the Materials and Methods section. A positive
signal is shown by brown color. Original magnification: 1006 and 4006. Black squares in 1006 pictures show approximately location of 4006
pictures.
doi:10.1371/journal.pone.0064441.g004
Figure 5. SDS-PAGE of purified native DMBT1gp340 from BAL and recombinant TFF proteins. A) Purified native DMBT1gp340 in the
reduced state visualized using silver staining. B) Purified non reduced and reduced recombinant TFF proteins staining using SafeStain staining. gTFF2:
Glycosylated TFF2, mTFF3: Monomeric TFF3 and dTFF3: Dimeric TFF3.
doi:10.1371/journal.pone.0064441.g005
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expression level was found to be more than ten-fold higher than
any other organ tested in an array of 20 different organs [34]. It is
not known whether the DMBT1 protein from the stomach is
different from DMBT1 proteins expressed in the lung or colon as
no information has been published on this. However, human
TFF3 has a wider expression profile on mucosal surfaces in general
and similar to the expression profile found for human and mouse
DMBT1 [6,13,34]. It remains an open question whether different
forms of DMBT1 from different tissues interact with different TFF
proteins? The pH values between the stomach and the rest of the
gastrointestinal tract are different. The surface structure of dimeric
TFF3 in solution, using nuclear magnetic resonance, followed by
comparison to monomeric TFF3 and dimeric TFF1 and TFF2
using computer modeling showed that the proteins display surface
differences outside the core regions [48]. These core regions are
believed to provide the scaffolding of the TFF proteins,
highlighting that the differences found between the proteins would
dictate the functional specificities of each protein [48]. It is
therefore tempting to speculate that the pH difference seen in the
gastrointestinal channel could have an influence on the function of
the different TFF proteins by changing the charge of amino and
carboxylated surface residues. Here we have only tested the
interaction between DMBT1gp340 and TFF proteins at a pH value
of 7.4 but it would be interesting to see if differences would be
observed at different pH values.
We showed that DMBT1gp340 was up regulated in inflamma-
tory bowel disease using a monoclonal antibody raised against
native DMBT1gp340 (Fig. 3). This is consistent with what is seen in
the literature measuring both the mRNA level as well as the
protein level seen in immunohistochemical analysis using other
antibodies raised against DMBT1 [26,27]. We found that DMBT1
and TFF proteins don’t co-localize in the same cells. Instead,
DMBT1 was localized to epithelial cells and TFF proteins to
goblet cells (Fig. 3 and 4). Despite this spatial separation, the
proteins would come in close proximity to each other in the
mucus, so that interactions could take place outside the cells. The
spatial separation of protein synthesis might serve to prevent the
formation of viscous mucus in secretory vesicles. DMBT1gp340 has
recently been found to be associated with mucins in the respiratory
tract [49]. Trefoil peptides are also found in the respiratory tract
[34,50,51]. Trefoil peptides and DMBT1 may therefore associate
with the gel-forming mucins and may form a gel-network
providing an immobilized reservoir of protective factors. This
finding may place DMBT in a central situation where it could
orchestrate different responses dependent on the molecules it is
interacting with as DMBT1 also has been found to bind to SP-A,
SP-D, complement factor C1q, Mannose Binding Lectin (MBL),
Figure 6. Binding of immobilized TFF proteins to DMBT1gp340. Serial diluted deglycosylated TFF2, glycosylated TFF2, monomeric TFF3 and
dimeric TFF3 was coated to ELISA plates. The interaction was tested using two-fold serial diluted concentration of DMBTgp340 starting from 600 ng/
mL. The binding of DMBT1gp340 was detected using a polyclonal rabbit anti-gp340 antibody (K421) as described in the Materials and Methods section.
Serial dilution of recombinant TFF protein: 2 mg/mL (X), 1 mg/mL (&), 0.5 mg/mL (m), 0 mg/mL (N) and 2 mg/mL in EDTA (x). Each sample was done
in duplicates and performed independently three times. Representative results are shown.
doi:10.1371/journal.pone.0064441.g006
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lactoferrin and secretory IgA – all molecules of innate immunity
[16,17,46,47,52,53]. It has been suggested DMBT1 also has a role
in cell growth and differentiation [54] and in combination with the
finding that DMBT1 also interacts with TFF proteins, which are
also involved in cell growth and differentiation [55], highlights the
potential multifunctional role of DMBT1 in vivo. Further research
is required to elucidate the in vivo role(s) of DMBT1 and what
function each form of this multifaceted molecule undertakes.
We conclude that differently sized forms of DMBT1 are
expressed between tissues that are differentially recognized by
monoclonal antibodies raised against DMBT1gp340. A form of
DMBT1 expressed in colon tissue was found to be specific for
the monoclonal antibody Hyb213-6 and was not recognized by
the monoclonal antibody Hyb213-1. DMBT1 was strongly up
regulated in inflammatory bowel disease such as UC and DC,
in epithelial cells adjacent to the TFF3-producing goblet cells.
Furthermore, DMBT1gp340 bound to recombinant dimeric
TFF3 in a solid-phase ELISA assay, but not to monomeric
TFF3 or glycosylated or non-glycosylated TFF2. As animal
models have shown that lack of DMBT1 and TFF proteins
increase the susceptibly to inflammatory bowel diseases, the
DMBT1-TFF3 interaction may have a role in the homeostasis
of the normal gastrointestinal tract and in inflammatory bowel
diseases in vivo.
Supporting Information
Figure S1 Intensity of TFF3 staining in normal human
colon and inflammatory bowel diseases. A) A dilution
series from 1:10,000 to 1:3,200,000 was performed on normal
human colon tissue to identify a dilution that gave weak but
specific staining of TFF3. Original magnification 100x. B) TFF3
staining (1:400,000) in normal colon and the inflammatory bowel
diseases ulcerative colitis and Crohn’s disease. Tissue sections were
stained using the polyclonal antibody raised against TFF3 and an
indirect immunperoxidase technique and counterstained with
Mayer’s hematoxylin as described in the Materials and Methods
section. A positive signal is shown by brown color. Original
magnification: 100x and 400x. Black squares in 100x pictures
show approximately location of 400x pictures.
(TIF)
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